Volume 3.18 | May 12

Mammary Cell News 3.18 May 12, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Mammary Cell News on Twitter

Researcher Maps Far-Reaching Effects of Estrogen Signaling in Breast Cancer Cells
A researcher has identified the most comprehensive measurement to date of estrogen’s effect on breast cancer cells, showing for the first time how immediate and extensive the effect is. [Press release from the University of Texas Southwestern Medical Center discussing online prepublication in Cell]



Genomic Test Shows Promise as Predictor of Chemotherapy Response, Survival for Women with Invasive Breast Cancer
A new genomic test combining multiple signatures – a patient’s estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity – shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in the Journal of the American Medical Association]

Normal Stem Cells Made to Look and Act Like Cancer Stem Cells
Researchers, after isolating normal stem cells that form the developing placenta, have given them the same properties of stem cells associated with an aggressive type of breast cancer. [Press release from the University of North Carolina at Chapel Hill School of Medicine discussing online prepublication in Cell Stem Cell]

Coffee Consumption Modifies Risk of Breast Cancer
In a new study a research group shows that drinking coffee may reduce the risk of estrogen receptor-negative breast cancer in women. [Press release from Karolinska Institutet discussing online prepublication in Breast Cancer Research]

Parsley, Celery Carry Crucial Component for Fight Against Breast Cancer, Researcher Finds
In a new study, a researcher has found that a compound in parsley and other plant products, including fruits and nuts, can stop certain breast cancer tumor cells from multiplying and growing. [Press release from the University of Missouri discussing online prepublication in Cancer Prevention Research]

Strong Evidence Supports Prognostic Value of Circulating Tumor Cells in Breast Cancer
Researchers have reported the strongest proof yet that evidence of ‘circulating tumor cells’ found in samples of a patient’s blood is strongly linked to poor outcomes such as a short time to disease progression. [Press release from the European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Epigenetic Study Reveals New Insights into Breast Cancer
The most comprehensive analysis yet of the epigenetic modifications present in breast cancer has revealed potentially important new ways to detect and treat the disease, researchers have reported. [Press release from the European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Gene Expression Predicts Chemotherapy Sensitivity of Triple-Negative Breast Cancer
Researchers have identified an unexpected molecular marker that predicts how sensitive hard-to-treat triple-negative breast cancers are to chemotherapy. [Press release from the European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Breast Cancer Multi-Gene Tests Compared
Two multi-gene tests designed to predict the risk of disease progression and response to chemotherapy in breast cancer produce broadly similar results for high- and low-risk patients, but do not always agree in their predictions for those at intermediate risk, a new analysis shows. [Press release from the European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Protein Snapshots Reveal Clues to Breast Cancer Outcomes
Measuring the transfer of tiny amounts of energy from one protein to another on breast cancer cells has given scientists a detailed view of molecular interactions that could help predict how breast cancer patients will respond to particular therapies. [Press release from the European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Anti-Inflammatory Drug May Fight Breast Cancer
The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, researchers report. [Press release from the European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


A Rapid, Extensive, and Transient Transcriptional Response to Estrogen Signaling in Breast Cancer Cells
Scientists report the immediate effects of estrogen signaling on the transcriptome of breast cancer cells using global run-on and sequencing. [Cell]

MAP3K4/CBP-Regulated H2B Acetylation Controls Epithelial-Mesenchymal Transition in Trophoblast Stem Cells
Researchers show that MAP3K4 controls the activity of the histone acetyltransferase CBP, and that acetylation of histones H2A and H2B by CBP is required to maintain the epithelial phenotype. [Cell Stem Cell]

TGF-β Signaling Engages an ATM-CHK2-p53–Independent RAS-Induced Senescence and Prevents Malignant Transformation in Human Mammary Epithelial Cells
Investigators show here that finite lifespan human mammary epithelial cells undergo a p16/RB- and p53-independent oncogene-induced senescence in response to oncogenic RAS that requires TGF-β signaling. [Proc Natl Acad Sci U S A]

Akt2 Regulates All Akt Isoforms and Promotes Resistance to Hypoxia Through Induction of miR-21 Upon Oxygen Deprivation
Scientists show that both normal and tumor cells expressing the protein kinase Akt2 are more resistant to hypoxia than cells expressing Akt1 or Akt3. [Cancer Res]

BRCA1 Counteracts Progesterone Action by Ubiquitination Leading to Progesterone Receptor Degradation and Epigenetic Silencing of Target Promoters
Given the relevance of progesterone for normal mammary development and breast cancer formation, investigators searched for a functional relationship between BRCA1 and progesterone receptor (PR) in the PR-positive breast cancer cell line T47D. [Cancer Res]

WEE1 Kinase Targeting Combined with DNA Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
Preclinical studies with cancer cell lines and animal models demonstrated decreased cancer cell viability, reduced tumor burden and improved survival after WEE1 inhibition by siRNA or small molecule inhibitors that is enhanced by combination with conventional DNA-damaging therapy, such as radiotherapy and/or cytostatics. [Clin Cancer Res]

Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague-Dawley Rats
Researchers sought to identify nontoxic chemicals that would inhibit progestin-induced tumorigenesis. [Cancer Prev Res]


A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
The objective of this study is to develop a predictor of response and survival from chemotherapy for newly diagnosed invasive breast cancer. [JAMA]

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery for estrogen receptor–positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized Phase II neoadjuvant trial designed to select agents for Phase III investigations. [J Clin Oncol]

Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients with Metastatic Breast Cancer
This multicenter, randomized, double-blind, Phase II study assessed safety and efficacy of axitinib plus docetaxel in metastatic breast cancer. [J Clin Oncol]

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Researchers conducted a Phase II study of 17-AAG with trastuzumab in advanced trastuzumab-refractory HER2 positive breast cancer. [Clin Cancer Res]

Coffee Consumption Modifies Risk of Estrogen-Receptor Negative Breast Cancer
Investigators assessed the association between coffee consumption and postmenopausal breast cancer risk in a large population-based study (2,818 cases and 3,111 controls), overall, and stratified by estrogen receptor tumor subtypes. [Breast Cancer Res]


Myriad Genetics Licenses Novel Technology from Chronix Biomedical
Myriad Genetics, Inc. announced that it has signed an agreement to license proprietary technology for the early detection of cancer from Chronix Biomedical of San Jose, California. [Myriad Genetics, Inc. Press Release]

Cytheris, Centre Léon Bérard and ImmunID Announce Initiation of Clinical Trial to Evaluate Combination Regimen of IL-7 (CYT107) and XELODA® (Capecitabine) in Treatment of Metastatic Breast Cancer
Cytheris SA, the Centre Léon Bérard (Lyon), and ImmunID Technologies SAS (Grenoble) announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7 and a chemotherapeutic agent, XELODA® (capecitabine, Roche/Genentech), in the treatment of metastatic breast cancer. [Cytheris SA Press Release]

Dean/CEO Edward D. Miller to Retire in 2012
President Ronald J. Daniels sent a broadcast e-mail message to faculty and staff members at The Johns Hopkins University on Wednesday, May 4, announcing the decision to Edward D. Miller, dean of the Johns Hopkins School of Medicine and CEO of Johns Hopkins Medicine, to retire in 2012. [Johns Hopkins University Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Science AAAS Webinar: Identifying Novel Cancer Therapeutic Targets: Real-time, Label-free Cell Monitoring in RNAi Profiling
May 18, 2011

NEW Gordon Research Conferences: Cell Growth & Proliferation – Connecting Cell Cycle Regulation to Cancer Biology
June 26-July 1, 2011
Biddeford, United States

our events page to see a complete list of events in the mammary cell community.


Scientific Officer (The Institute of Cancer Research)

Post-doctoral Research Fellow (University of Ottawa)

Post-doctoral Fellow (University of Texas Medical School at Houston) 

Post-doctoral Research Associate (University of Wisconsin – Madison)

Post-doctoral Fellow (University of Texas Medical School at Houston)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us